Compositions and Methods for the Prevention and Treatment of Hearing Loss
Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.
1 . Use of an inhibitor of epidermal growth factor receptor (EGFR) signaling, for the prevention of hearing loss, wherein the inhibitor of EGFR signaling inhibits tyrosine kinase activity of EGFR, wherein said inhibitor of EGFR signaling is selected from the group consisting of: PELITINIB (CAS 257933-82-7), AZD3759 (CAS 1626387-80-1) and afatinib (CAS 439081-18-2).
2 . The method of claim 1 , further comprising administering one or more otoprotective or regenerative agents.
3 . A kit comprising an inhibitor of epidermal growth factor receptor (EGFR) signaling, for the prevention of hearing loss, wherein the inhibitor of EGFR signaling inhibits tyrosine kinase activity of EGFR, and instructions of an inhibitor of epidermal growth factor receptor (EGFR) signaling, for the prevention of hearing loss, wherein the inhibitor of EGFR signaling inhibits tyrosine kinase activity of EGFR, wherein said inhibitor of EGFR signaling is selected from the group consisting of: PELITINIB (CAS 257933-82-7), AZD3759 (CAS 1626387-80-1) and afatinib (CAS 439081-18-2).
4 . A method to prevent hearing loss comprising: orally administering to subject in need thereof a pharmaceutical composition comprised of: a sufficient amount of AZD3759 to prevent hearing loss from an ototoxic event.
5 . The method of claim 4 , further comprising administering one or more otoprotective or regenerative agents.